Page 38 - Alkermes News Today

NORTHAMPTON, MA / ACCESSWIRE / May 2, 2023 / Alkermes Athlone site recently received a 2023 award in the Life Sciences category at Ireland's 2023 Health & Safety Excellence Awards. This recognition is

Alkermes (NASDAQ:ALKS – Get Rating) issued an update on its FY 2023 earnings guidance on Thursday morning. The company provided earnings per share (EPS) guidance of 0-$0.23 for the period, compared to the consensus estimate of $0.07. The company issued revenue guidance of $1.13 billion-$1.25 billion, compared to the consensus revenue estimate of $1.19 billion. […]

Alkermes (NASDAQ:ALKS – Get Rating) updated its FY 2023 earnings guidance on Thursday. The company provided EPS guidance of 0-$0.23 for the period, compared to the consensus EPS estimate of $0.07. The company issued revenue guidance of $1.13 billion-$1.25 billion, compared to the consensus revenue estimate of $1.19 billion. Wall Street Analysts Forecast Growth Several […]

In a report released on April 27, Paul Matteis from Stifel Nicolaus maintained a Hold rating on Alkermes (ALKS – Research Report), with a ...

Alkermes (NASDAQ:ALKS – Get Rating) had its price objective upped by HC Wainwright from $32.00 to $34.00 in a research report sent to investors on Thursday morning, The Fly reports. Other analysts also recently issued research reports about the stock. JPMorgan Chase & Co. boosted their price objective on shares of Alkermes from $29.00 to […]

The biotech industry should thrive amid breakthrough developments and increasing investments this year. Therefore, fundamentally strong biotech stocks, Alkermes (ALKS) and Nippon Shinyaku (NPPNY) might be ideal buys. Read more.

Alkermes (NASDAQ:ALKS – Get Rating) had its target price hoisted by JPMorgan Chase & Co. from $29.00 to $31.00 in a report issued on Tuesday morning, The Fly reports. Several other research firms have also recently issued reports on ALKS. Mizuho raised their target price on Alkermes from $36.00 to $37.00 and gave the stock […]

Alkermes (NASDAQ:ALKS – Get Rating) had its price target boosted by JPMorgan Chase & Co. from $29.00 to $31.00 in a research report sent to investors on Tuesday, The Fly reports. Several other equities research analysts have also recently issued reports on ALKS. Mizuho boosted their price target on Alkermes from $36.00 to $37.00 and […]

Alkermes (NASDAQ:ALKS – Get Rating) updated its FY23 earnings guidance on Wednesday. The company provided earnings per share (EPS) guidance of $0.00-0.23 for the period, compared to the consensus estimate of $0.09. The company issued revenue guidance of $1.13-1.25 billion, compared to the consensus revenue estimate of $1.21 billion. Analyst Ratings Changes Several research firms […]

In a report released yesterday, Chris Shibutani from Goldman Sachs reiterated a Buy rating on Alkermes (ALKS – Research Report). The compa...